Celastrol treatment resulted in a substantial decline in MDA serum level by about 0.91 folds with a considerable elevation in CAT and TAC serum levels by about 1.38 and 19 folds, respectively, compared to the DKD group (Fig. 2A: C). This evidence concerns the gene CAT and diabetic kidney disease.